Figure 1From: Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial Map of the 3’ end of the MGMT CpG island, showing the CpGs analysed in this study (74–89) and the regions examined in some other studies as well as part of exon 1 of MGMT . Back to article page